Abstract Up to 30% of acute myeloid leukemia (AML) patients face unfavorable outcomes due to the FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation. Although FLT3 inhibitors show encouraging outcomes in treatment. they fail to eliminate leukemia stem cells. the origin of persistent and resistant lesions. https://www.roneverhart.com/NeOn-Zero-Lefty-M390-BLADE-TITANIUM-HANDLE-MRBS-p11472/